Potentially Resectable Hepatocellular Carcinoma Clinical Trials in Shanghai, Shanghai Municipality

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)